COVID-19 Phenotypes and Comorbidity: A Data-Driven, Pattern Recognition Approach Using National Representative Data from the United States
Ημερομηνία
2022Γλώσσα
en
Λέξη-κλειδί
Επιτομή
The aim of our study was to determine COVID-19 syndromic phenotypes in a data-driven manner using the survey results based on survey results from Carnegie Mellon University’s Delphi Group. Monthly survey results (>1 million responders per month; 320,326 responders with a certain COVID-19 test status and disease duration <30 days were included in this study) were used sequen-tially in identifying and validating COVID-19 syndromic phenotypes. Logistic Regression-weighted multiple correspondence analysis (LRW-MCA) was used as a preprocessing procedure, in order to weigh and transform symptoms recorded by the survey to eigenspace coordinates, capturing a total variance of >75%. These scores, along with symptom duration, were subsequently used by the Two Step Clustering algorithm to produce symptom clusters. Post-hoc logistic regression models adjusting for age, gender, and comorbidities and confirmatory linear principal components analyses were used to further explore the data. Model creation, based on August’s 66,165 included responders, was subsequently validated in data from March–December 2020. Five validated COVID-19 syndromes were identified in August: 1. Afebrile (0%), Non-Coughing (0%), Oligosymptomatic (ANCOS); 2. Febrile (100%) Multisymptomatic (FMS); 3. Afebrile (0%) Coughing (100%) Oligosymptomatic (ACOS); 4. Oligosymptomatic with additional self-described symptoms (100%; OSDS); 5. Olfac-tion/Gustatory Impairment Predominant (100%; OGIP). Our findings indicate that the COVID-19 spectrum may be undetectable when applying current disease definitions focusing on respiratory symptoms alone. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Genotype-Phenotype Relationships in Inheritable Idiopathic Pulmonary Fibrosis: A Greek National Cohort Study
Manali E.D., Kannengiesser C., Borie R., Ba I., Bouros D., Markopoulou A., Antoniou K., Kolilekas L., Papaioannou A.I., Tzilas V., Tzouvelekis A., Daniil Z., Fouka E., Papakosta D., Xyfteri A., Karakatsani A., Loukides S., Korbila I., Tomos I.P., Konstantinidis A.K., Gogali A., Steiropoulos P., Papanikolaou I.C., Bazaka C., Haritou A., Vassilakopoulos T., Maniati M., Kagouridis K., Markozannes E., Bouros E., Rampiadou C., Kounti G., Trachalaki A., Dimeas I., Karampitsakos T., Lyberopoulos P., Malamadakis N., Spyropoulou S., Revy P., Lainey E., Dieudé P., Rebah K., Ménard C., Oudin C., Masson C., Plessier A., Legendre M., Nathan N., Coulomb-L'hermine A., Clement A., Amselem S., Boileau C., Crestani B., Papiris S. (2022)Background: Monogenic and polygenic inheritances are evidenced for idiopathic pulmonary fibrosis (IPF). Pathogenic variations in surfactant protein-related genes, telomere-related genes (TRGs), and a single-nucleotide ... -
Netherton Syndrome: A Genotype-Phenotype Review
Sarri C.A., Roussaki-Schulze A., Vasilopoulos Y., Zafiriou E., Patsatsi A., Stamatis C., Gidarokosta P., Sotiriadis D., Sarafidou T., Mamuris Z. (2017)Netherton syndrome (OMIM #256500) is a rare but severe autosomal recessive form of ichthyosis that affects the skin, hair, and immune system. The identification of SPINK5, which encodes for the serine protease inhibitor ... -
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
Fountzilas G., Giannoulatou E., Alexopoulou Z., Zagouri F., Timotheadou E., Papadopoulou K., Lakis S., Bobos M., Poulios C., Sotiropoulou M., Lyberopoulou A., Gogas H., Pentheroudakis G., Pectasides D., Koutras A., Christodoulou C., Papandreou C., Samantas E., Papakostas P., Kosmidis P., Bafaloukos D., Karanikiotis C., Dimopoulos M.-A., Kotoula V. (2016)Background: We investigated the impact of PIK3CA and TP53 mutations and p53 protein status on the outcome of patients who had been treated with adjuvant anthracycline-taxane chemotherapy within clinical trials in the pre- ...